Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17.beta.-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17.beta.-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17.beta.-hydroxysteroid dehydrogenase.
RELATED APPLICATION
This patent application is a regular, non-provisional application claiming priority of provisional application Serial No. 60/077,510, filed Mar. 11, 1998, the entire specification of which is incorporated by reference as though fully set forth herein. This application also claims priority of U.S. Provisional Application Serial No. 60/095,623, filed Aug. 7, 1998, the entire disclosure of which is incorporated by reference as though fully set forth herein.
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17.beta.-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17.beta.-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17.beta.-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17.beta.-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17.beta.-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17.beta.-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17.beta.-hydroxysteroid dehydrogenase enzymes.
The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I ##STR00001## in which R.sup.2 means a C.sub.1-C.sub.8-alkyl group, a C.sub.1-C.sub.8-alkyloxy group or a halogen atom, R.sup.13 means a hydrogen atom or a methyl group, R.sup.17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17.beta.-hydroxy steroid dehydro-genase type 1.
